Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Colorcon
Moodys
Baxter
Johnson and Johnson

Last Updated: January 17, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Marizomib


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Marizomib?

Marizomib is an investigational drug.

There have been 12 clinical trials for Marizomib. The most recent clinical trial was a Phase 2 trial, which was initiated on July 26th 2018.

The most common disease conditions in clinical trials are Glioma, Neoplasms, Plasma Cell, and Glioblastoma. The leading clinical trial sponsors are Celgene, Triphase Research and Development I Corporation, and Dana-Farber Cancer Institute.

There are six hundred and four US patents protecting this investigational drug and five international patents.

Recent Clinical Trials for Marizomib
TitleSponsorPhase
Marizomib Central Nervous System (CNS)Bristol-Myers SquibbPhase 2
Marizomib Central Nervous System (CNS)Dana-Farber Cancer InstitutePhase 2
Phase I Study of Marizomib + Panobinostat for Children With DIPGCelgenePhase 1

See all Marizomib clinical trials

Clinical Trial Summary for Marizomib

Top disease conditions for Marizomib
Top clinical trial sponsors for Marizomib

See all Marizomib clinical trials

US Patents for Marizomib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Marizomib ⤷  Try it Free Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity The University of North Carolina at Chapel Hill (Chapel Hill, NC) ⤷  Try it Free
Marizomib ⤷  Try it Free Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells Selecta Biosciences, Inc. (Watertown, MA) ⤷  Try it Free
Marizomib ⤷  Try it Free Low, immune enhancing, dose mtor inhibitors and uses thereof Novartis AG (Basel, CH) ⤷  Try it Free
Marizomib ⤷  Try it Free Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor Pharmacyclics LLC (Sunnyvale, CA) ⤷  Try it Free
Marizomib ⤷  Try it Free Small molecule HSP70 inhibitors The Trustees of the University of Pennsylvania (Philadelphia, PA) The Wistar Institute of Anatomy and Biology (Philadelphia, PA) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Marizomib

Drugname Country Document Number Estimated Expiration Related US Patent
Marizomib Australia AU2015244171 2034-04-11 ⤷  Try it Free
Marizomib Australia AU2015244179 2034-04-11 ⤷  Try it Free
Marizomib Canada CA2945128 2034-04-11 ⤷  Try it Free
Marizomib Canada CA2945129 2034-04-11 ⤷  Try it Free
Marizomib China CN106414451 2034-04-11 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Colorcon
Moodys
Baxter
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.